



Shionogi Announces Investment in Dioseve, Inc. through Its CVC Activities

OSAKA, Japan, June 12, 2026 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; hereinafter, "Shionogi") today announced that, as part of its corporate venture capital (CVC) initiatives, it has invested in Dioseve, Inc. (Head Office: Tokyo, Japan; hereinafter, "Dioseve")

Dioseve, Inc. is a startup company leveraging its proprietary technology to efficiently induce oocytes and ovarian somatic cells from iPS cells, aiming to provide innovative solutions for individuals who wish to have children. The company's technology is expected to contribute to the further advancement of assisted reproductive medicine, including in vitro fertilization and in vitro maturation.

In April 2025, Shionogi established its Corporate Venture Capital (CVC) to explore next-generation growth opportunities in new markets and technology areas. The CVC targets a broad range of investment areas beyond pharmaceuticals, including technology, infrastructure, and resources. Through these activities, Shionogi seeks to create new values that contribute to addressing social challenges and advancing healthcare. Through its CVC activities, Shionogi aims to build early-stage partnerships with startup companies that possess innovative technologies and business ideas, supporting them by leveraging Shionogi's research and development capabilities, business experience, and network—thereby fostering relationships that contribute to mutual growth.

Website: <https://www.shionogi.com/global/en/innovation/cvc.html>

Company Overview

Dioseve, Inc.

Headquarters: 1-17-8 Shin-Kiba, Koto-ku, Tokyo Mitsui Link Lab Shin-Kiba 2, Room 223

Management: Kazuma Kishida, CEO

Established: June 30, 2021

Business: Research development of assisted reproductive technology using oocytes and ovarian somatic cells derived from iPS cells

Website: <https://dioseve.com/en/>

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks,

which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact

SHIONOGI Website Inquiry Form: <https://www.shionogi.com/global/en/contact.html>